Literature DB >> 26917195

The impact of B-type natriuretic peptide levels on the suppression of accompanying atrial fibrillation in Wolff-Parkinson-White syndrome patients after accessory pathway ablation.

Mihoko Kawabata1, Masahiko Goya2, Takamitsu Takagi3, Shu Yamashita4, Shinsuke Iwai5, Masahito Suzuki6, Tomomasa Takamiya7, Tomofumi Nakamura7, Tatsuya Hayashi8, Atsuhiko Yagishita4, Takeshi Sasaki2, Yoshihide Takahashi8, Yuhichi Ono9, Hitoshi Hachiya3, Yasuteru Yamauchi4, Kenichiro Otomo9, Junichi Nitta6, Kaoru Okishige5, Mitsuhiro Nishizaki7, Yoshito Iesaka3, Mitsuaki Isobe10, Kenzo Hirao2.   

Abstract

BACKGROUND: Atrial fibrillation (AF) often coexists with Wolff-Parkinson-White (WPW) syndrome. We compared the efficacy of Kent bundle ablation alone and additional AF ablation on accompanying AF, and examined which patients would still have a risk of AF after successful Kent bundle ablation.
METHODS: This retrospective multicenter study included 96 patients (56±15 years, 72 male) with WPW syndrome and AF undergoing Kent bundle ablation. Some patients underwent simultaneous pulmonary vein isolation (PVI) for AF. The incidence of post-procedural AF was examined.
RESULTS: Sixty-four patients underwent only Kent bundle ablation (Kent-only group) and 32 also underwent PVI (+PVI group). There was no significant difference in the basic patient characteristics between the groups. Additional PVI did not improve the freedom from residual AF compared to Kent bundle ablation alone (p=0.53). In the Kent-only group, AF episodes remained in 25.0% during the follow-up (709 days). A univariate analysis showed that age ≥60 years, left atrial dimension ≥38mm, B-type natriuretic peptide (BNP) ≥40pg/ml, and concomitant hypertension were predictive factors for residual AF. However, in the multivariate analysis, only BNP ≥40pg/ml remained as an independent predictive factor (HR=17.1 and CI: 2.3-128.2; p=0.006).
CONCLUSIONS: Among patients with WPW syndrome and AF, Kent bundle ablation alone may have a sufficient clinical impact of preventing recurrence of AF in select patients. Screening the BNP level would help decide the strategy to manage those patients.
Copyright © 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; B-type natriuretic peptide; Catheter ablation; Wolff-Parkinson-White syndrome

Mesh:

Substances:

Year:  2016        PMID: 26917195     DOI: 10.1016/j.jjcc.2016.01.007

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  2 in total

1.  Advanced interatrial block predicts recurrence of atrial fibrillation after accessory pathway ablation in patients with Wolff-Parkinson-White syndrome.

Authors:  Jin-Tao Wu; Dan-Qing Zhao; Fei-Fei Li; Rui Wu; Xian-Wei Fan; Guang-Ling Hu; Min-Fu Bai; Hai-Tao Yang; Li-Jie Yan; Jing-Jing Liu; Xian-Jing Xu; Shan-Ling Wang; Ying-Jie Chu
Journal:  Clin Cardiol       Date:  2019-06-26       Impact factor: 2.882

2.  Effect of pulmonary vein isolation on atrial fibrillation recurrence after accessory pathway ablation in patients with Wolff-Parkinson-White syndrome.

Authors:  Jin-Tao Wu; Dan-Qing Zhao; Fei-Fei Li; Lei-Ming Zhang; Juan Hu; Xian-Wei Fan; Guang-Ling Hu; Hai-Tao Yang; Li-Jie Yan; Jing-Jing Liu; Xian-Jing Xu; Shan-Ling Wang; Ying-Jie Chu
Journal:  Clin Cardiol       Date:  2020-10-01       Impact factor: 2.882

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.